NCT03678610

Brief Summary

Using Latrunculin A and Ionomycin would improve the outcome of ICSI if the handling medium during the ICSI procedure has them.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
700

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 19, 2018

Completed
6 days until next milestone

Study Start

First participant enrolled

September 25, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2019

Completed
Last Updated

May 7, 2019

Status Verified

May 1, 2019

Enrollment Period

7 months

First QC Date

September 17, 2018

Last Update Submit

May 5, 2019

Conditions

Infertility

Outcome Measures

Primary Outcomes (1)

  • Fertilization rate

    6 days of culture

Secondary Outcomes (4)

  • Rates of Blastocyst formation and quality

    6 days of culture

  • embryo utilization rate

    6 days of culture

  • clinical pregnancy rate

    three months

  • ongoing pregnancy rate

    12 weeks

Study Arms (2)

ICSI medium supplemented with Ionomycin and Latrunculin A

EXPERIMENTAL
Other: Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A

ICSI medium as it is

NO INTERVENTION

Interventions

Doing ICSI I a medium supplemented with Ionomycin and Latrunculin AOTHER

Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes

ICSI medium supplemented with Ionomycin and Latrunculin A

Eligibility Criteria

Age18 Years - 42 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • indication for ICSI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Qena Fertility Center

Qina, Qena Governorate, 123456, Egypt

Location

Banon Assiut

Asyut, Egypt

Location

IbnSina IVF Center

Sohag, Egypt

Location

MeSH Terms

Conditions

Infertility

Interventions

Ionomycinlatrunculin A

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Fatty Acids, UnsaturatedFatty AcidsLipids

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
IVF Lab Director

Study Record Dates

First Submitted

September 17, 2018

First Posted

September 19, 2018

Study Start

September 25, 2018

Primary Completion

May 1, 2019

Study Completion

May 1, 2019

Last Updated

May 7, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations

EG(3)